Effectiveness of Patiromer Versus Sodium Zirconium Cyclosilicate for the Management of Acute Hyperkalemia
CONCLUSIONS AND RELEVANCE: This study represents the first head-to-head comparison of patiromer and SZC in the setting of acute hyperkalemia. No difference in effectiveness between patiromer and SZC in reducing serum potassium was seen. Both agents can be considered in acute hyperkalemia management.PMID:37953506 | DOI:10.1177/10600280231209968 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 13, 2023 Category: Drugs & Pharmacology Authors: Alison Rydell Corianne Thackrey Maryam Molki Brandon P Mullins Source Type: research

Effectiveness of Patiromer Versus Sodium Zirconium Cyclosilicate for the Management of Acute Hyperkalemia
CONCLUSIONS AND RELEVANCE: This study represents the first head-to-head comparison of patiromer and SZC in the setting of acute hyperkalemia. No difference in effectiveness between patiromer and SZC in reducing serum potassium was seen. Both agents can be considered in acute hyperkalemia management.PMID:37953506 | DOI:10.1177/10600280231209968 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 13, 2023 Category: Drugs & Pharmacology Authors: Alison Rydell Corianne Thackrey Maryam Molki Brandon P Mullins Source Type: research

Risk of Tendon Injury in Patients Treated With Fluoroquinolone (FQ) Versus Non-Fluoroquinolone Antibiotics for Community-Acquired Pneumonia (CAP)
CONCLUSIONS AND RELEVANCE: Prescribers should recognize the risk of tendon injury within 1 month of FQ use when considering treatment regimens for CAP and use alternative options with lower risk whenever possible.PMID:37946374 | DOI:10.1177/10600280231210275 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 10, 2023 Category: Drugs & Pharmacology Authors: Virginia H Fleming Jianing Xu Xianyan Chen Daniel Hall Robin L Southwood Source Type: research

Risk of Tendon Injury in Patients Treated With Fluoroquinolone (FQ) Versus Non-Fluoroquinolone Antibiotics for Community-Acquired Pneumonia (CAP)
CONCLUSIONS AND RELEVANCE: Prescribers should recognize the risk of tendon injury within 1 month of FQ use when considering treatment regimens for CAP and use alternative options with lower risk whenever possible.PMID:37946374 | DOI:10.1177/10600280231210275 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 10, 2023 Category: Drugs & Pharmacology Authors: Virginia H Fleming Jianing Xu Xianyan Chen Daniel Hall Robin L Southwood Source Type: research

Risk of Tendon Injury in Patients Treated With Fluoroquinolone (FQ) Versus Non-Fluoroquinolone Antibiotics for Community-Acquired Pneumonia (CAP)
CONCLUSIONS AND RELEVANCE: Prescribers should recognize the risk of tendon injury within 1 month of FQ use when considering treatment regimens for CAP and use alternative options with lower risk whenever possible.PMID:37946374 | DOI:10.1177/10600280231210275 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 10, 2023 Category: Drugs & Pharmacology Authors: Virginia H Fleming Jianing Xu Xianyan Chen Daniel Hall Robin L Southwood Source Type: research

Fanconi Syndrome in Patients With Human Immunodeficiency Virus Treated With Tenofovir-Based Antiretroviral Therapy: A Systematic Literature Review
CONCLUSIONS: Occurrence of FS is low in patients with HIV treated with tenofovir-based regimens. Concomitant use of ritonavir may increase risk of FS. TAF may be a safer alternative than TDF in terms of nephrotoxicity.PMID:37932920 | DOI:10.1177/10600280231206703 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 7, 2023 Category: Drugs & Pharmacology Authors: Mrinmayee Joshi Brendan Clark Todd A Lee Source Type: research

Fanconi Syndrome in Patients With Human Immunodeficiency Virus Treated With Tenofovir-Based Antiretroviral Therapy: A Systematic Literature Review
CONCLUSIONS: Occurrence of FS is low in patients with HIV treated with tenofovir-based regimens. Concomitant use of ritonavir may increase risk of FS. TAF may be a safer alternative than TDF in terms of nephrotoxicity.PMID:37932920 | DOI:10.1177/10600280231206703 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 7, 2023 Category: Drugs & Pharmacology Authors: Mrinmayee Joshi Brendan Clark Todd A Lee Source Type: research

Fanconi Syndrome in Patients With Human Immunodeficiency Virus Treated With Tenofovir-Based Antiretroviral Therapy: A Systematic Literature Review
CONCLUSIONS: Occurrence of FS is low in patients with HIV treated with tenofovir-based regimens. Concomitant use of ritonavir may increase risk of FS. TAF may be a safer alternative than TDF in terms of nephrotoxicity.PMID:37932920 | DOI:10.1177/10600280231206703 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 7, 2023 Category: Drugs & Pharmacology Authors: Mrinmayee Joshi Brendan Clark Todd A Lee Source Type: research

The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review
CONCLUSIONS: Psilocybin has demonstrated tolerability and safety in recent literature that has investigated its therapeutic potential in a variety of psychiatric or substance-dependence conditions.PMID:37902038 | DOI:10.1177/10600280231205645 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 30, 2023 Category: Drugs & Pharmacology Authors: Dana Kaminski Justin P Reinert Source Type: research

The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review
CONCLUSIONS: Psilocybin has demonstrated tolerability and safety in recent literature that has investigated its therapeutic potential in a variety of psychiatric or substance-dependence conditions.PMID:37902038 | DOI:10.1177/10600280231205645 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 30, 2023 Category: Drugs & Pharmacology Authors: Dana Kaminski Justin P Reinert Source Type: research

The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review
CONCLUSIONS: Psilocybin has demonstrated tolerability and safety in recent literature that has investigated its therapeutic potential in a variety of psychiatric or substance-dependence conditions.PMID:37902038 | DOI:10.1177/10600280231205645 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 30, 2023 Category: Drugs & Pharmacology Authors: Dana Kaminski Justin P Reinert Source Type: research

The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review
CONCLUSIONS: Psilocybin has demonstrated tolerability and safety in recent literature that has investigated its therapeutic potential in a variety of psychiatric or substance-dependence conditions.PMID:37902038 | DOI:10.1177/10600280231205645 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 30, 2023 Category: Drugs & Pharmacology Authors: Dana Kaminski Justin P Reinert Source Type: research

The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review
CONCLUSIONS: Psilocybin has demonstrated tolerability and safety in recent literature that has investigated its therapeutic potential in a variety of psychiatric or substance-dependence conditions.PMID:37902038 | DOI:10.1177/10600280231205645 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 30, 2023 Category: Drugs & Pharmacology Authors: Dana Kaminski Justin P Reinert Source Type: research

The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review
CONCLUSIONS: Psilocybin has demonstrated tolerability and safety in recent literature that has investigated its therapeutic potential in a variety of psychiatric or substance-dependence conditions.PMID:37902038 | DOI:10.1177/10600280231205645 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 30, 2023 Category: Drugs & Pharmacology Authors: Dana Kaminski Justin P Reinert Source Type: research

Zavegepant Intranasal Spray for Migraines
CONCLUSION: Zavegepant may be a convenient and useful acute treatment option for migraines with and without aura.PMID:37897226 | DOI:10.1177/10600280231209439 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 28, 2023 Category: Drugs & Pharmacology Authors: Amber Lanae Martirosov Christopher Giuliano Macy Shupp Sarah Channey Pramodini B Kale-Pradhan Source Type: research